Head and Neck Squamous Cell Carcinoma: Epidemiology Forecast to 2034

Head and Neck Squamous Cell Carcinoma: Epidemiology Forecast to 2034

Summary

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10] code = C00-C06); the salivary glands (ICD-10 code = C07-C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09-C14); the nose, sinuses, and related structures (ICD-10 code = C30-C31), and the larynx (ICD-10 code = C32) (World Health Organization, 2013). HNSCC usually begins in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck. More than 80% of all oral cavity and pharynx cancers are estimated to be squamous cell carcinomas (Howlader et al., 2020; National Cancer Institute, 2021).

In the 8MM, the diagnosed incident cases of HNSCC are expected to increase from 297,707 cases in 2024 to 357,960 cases in 2034, at an annual growth rate (AGR) of 2.02%. In 2034, urban China will have the highest number of diagnosed incident cases of HNSCC in the 8MM, with 166,519 diagnosed incident cases, whereas Italy will have the fewest diagnosed incident cases with 13,121 cases. In the 8MM, the five-year diagnosed prevalent cases of HNSCC are expected to increase from 915,055 cases in 2024 to 1,082,521 cases in 2034, at an AGR of 1.83%. GlobalData epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of HNSCC to the changes in diagnosed incidence rate, regression trend analysis, changes in survival rates, and population dynamics in each market.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNSCC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report provides a 10-year epidemiological forecast of the diagnosed incident cases of HNSCC. In this analysis, HNSCC is divided into the following groups -

• Cancers of the lip, oral cavity, pharynx, nasal cavity/paranasal sinuses, and larynx (ICD-10 = C00-C06, C09, C12-C14, C30-C32, and C10 [HPV-])
• Oropharynx cancer (ICD-10 = C10)
• Nasopharynx cancer (ICD-10 = C11)
• Other HNSCC sites - salivary gland cancer (ICD-10 = C07-C08)

Each of the four groups is further segmented by risk factor (tobacco smoking history), histology distribution (squamous cell and non-squamous cell), and clinical stage at diagnosis among the squamous cell carcinomas. Additionally, the diagnosed incident cases of oropharynx cancer were further segmented by risk factor (human papillomavirus infection positive [HPV+] and negative [HPV-]) and the diagnosed incident cases nasopharynx cancer were segmented by the risk factor of Epstein Barr virus infection positive (EBV+). The report provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of each of the four groups. The model accompanying this report also provides epidermal growth factor receptor (EGFR) mutation and programmed death-ligand 1 (PD-L1) expression (by combined positive score [CPS]), and surgical and radiotherapy versus systemic treatment among the diagnosed incident cases of the four groups.Reasons to Buy

• The Head and neck squamous cell carcinoma (HNSCC) epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global HNSCC market.
• Quantify patient populations in the global HNSCC market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HNSCC therapeutics in each of the markets covered.